Iterum Therapeutics Plc (ITRM)

NASDAQ:ITRM

ITRM

Iterum Therapeutics

RESEARCH TOOLSreports

Iterum Therapeutics (ITRM) Price & Analysis

Compare

954 Followers

ITRM Stock Chart & Stats

$0.34

-$0.04(-2.14%)

At close: Jan 08 4:00 PM EST

$0.34

-$0.04(-2.14%)

Day’s Range― - ―

52-Week Range$0.14 - $1.48

Previous CloseN/A

Volume220.96K

Average Volume (3M)813.22K

Market Cap

$8.99M

Enterprise Value$31.68M

Total Cash (Recent Filing)$11.00M

Total Debt (Recent Filing)$33.73M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding52,835,200

10 Day Avg. Volume1,119,323

30 Day Avg. Volume813,222

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)-8.54

Price to Sales (P/S)0.00

P/FCF Ratio-1.30

Enterprise Value/Market Cap3.52

Enterprise Value/Revenue81.22

Enterprise Value/Gross Profit-47.42

Enterprise Value/Ebitda-1.37

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)-0.31

Revenue Forecast (FY)$9.38M

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyAnalyst highlights late-stage trial results that showed ORLYNVAH outperformed conventional antibiotics, positioning the medicine as a potential option for antibiotic-resistant infections.

Commercial Strategy And AwarenessAnalyst observes that targeted market research and extensive pre-commercialization activities should help drive awareness among infectious disease specialists, primary care doctors and OBGYNs, supporting a gradual revenue ramp.

Product DifferentiationAnalyst notes ORLYNVAH is the first and only oral penem in the U.S., giving the company a clear product advantage in treating complicated urinary tract infections.

Bears Say

Earnings PerformanceAnalyst points out a quarterly EPS shortfall versus expectations, which could erode investor confidence and increase near-term financing concerns.

Limited Launch ScaleAnalyst warns that an initial launch concentrated in a small number of territories with limited resources produces a muted early sales trajectory and slower market penetration.

Payer Coverage And Capital ConstraintsAnalyst cautions that low payer coverage combined with capital constraints raises commercial risk and may impede the company’s ability to expand patient access and fund growth initiatives.

Iterum Therapeutics News

Iterum Therapeutics cut to Hold at Maxim after delisting notice

As previously reported, Maxim downgraded Iterum Therapeutics (ITRM) to Hold from Buy. The firm cites the company’s filing...

21d ago

ITRM

Iterum Therapeutics downgraded to Hold from Buy at Maxim

Maxim analyst Jason McCarthy downgraded Iterum Therapeutics (ITRM) to Hold from Buy. Published first on TheFly – the...

21d ago

ITRM

Morning News Wrap-Up 3/3/26: Tuesday’s Biggest Stock Market Stories!

Tuesday’s stock market stories are ready to go in our latest daily wrap-up. ...

22d ago

AMD

Why Is Iterum Therapeutics Stock (ITRM) Down Today?

Iterum Therapeutics stock fell on Tuesday after the company revealed a delisting notice. ...

22d ago

ITRM

NDAQ

ITRM Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Iterum Therapeutics (ITRM) is scheduled to report 4th quarter earnings on 03/12/2026. Regarding Q4 estimates, Wall Street analysts...

15d ago

ITRM

Iterum Therapeutics Appeals Nasdaq Delisting, Explores Strategic Alternatives

Iterum Therapeutics ( ($ITRM) ) has issued an update. On February 24, 2026, Iterum Therapeutics received a delisting...

22d ago

ITRM

Iterum Therapeutics Faces Nasdaq Delisting, Weighs Strategic Options

Iterum Therapeutics ( ($ITRM) ) just unveiled an update. On February 24, 2026, Iterum Therapeutics disclosed that it...

23d ago

ITRM

Iterum Therapeutics Shareholders Reject Key Capital Proposals

Iterum Therapeutics ( ($ITRM) ) has shared an update. On February 18, 2026, Iterum Therapeutics plc shareholders rejected...

1M ago

ITRM

Iterum provides business update, expanded market access for Orlynvah

Iterum Therapeutics (ITRM) provided a business update. Market Access Update: Medicare Part D Milestone: The company announces another...

1M ago

ITRM

Iterum Therapeutics provides market access update

The company said, “Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH’s market access continues to accelerate....

3M ago

ITRM

Iterum Therapeutics provides business update

Iterum Therapeutics (ITRM) provided a business update. Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH’s market...

3M ago

ITRM

Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge

Iterum Therapeutics ( ($ITRM) ) has issued an announcement. On December 11, 2025, Iterum Therapeutics received a notification...

3M ago

ITRM

Buy Rating Affirmed for Iterum Therapeutics Amid Strategic Launch of ORLYNVAH and Strong Market Positioning

Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Iterum Therapeutics, with a price target of...

4M ago

ITRM

Iterum Therapeutics says ORLYNVAH access ‘continues to grow’

The company said, “Market Access Update: Expanding Reimbursement Footprint: ORLYNVAH’s access continues to grow-both with and without prior...

4M ago

ITRM

ITRM FAQ

What was Iterum Therapeutics Plc’s price range in the past 12 months?

Iterum Therapeutics Plc lowest stock price was $0.14 and its highest was $1.48 in the past 12 months.

What is Iterum Therapeutics Plc’s market cap?

Iterum Therapeutics Plc’s market cap is $8.99M.

When is Iterum Therapeutics Plc’s upcoming earnings report date?

Iterum Therapeutics Plc’s upcoming earnings report date is May 20, 2026 which is in 56 days.

How were Iterum Therapeutics Plc’s earnings last quarter?

Currently, no data Available

Is Iterum Therapeutics Plc overvalued?

According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Iterum Therapeutics Plc pay dividends?

Iterum Therapeutics Plc does not currently pay dividends.

What is Iterum Therapeutics Plc’s EPS estimate?

Iterum Therapeutics Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Iterum Therapeutics Plc have?

Iterum Therapeutics Plc has 52,835,200 shares outstanding.

What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Iterum Therapeutics Plc?

Currently, no hedge funds are holding shares in ITRM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Iterum Therapeutics Plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics (ITRM) Earnings & Revenues

Historic Earnings Reports

ITRM Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted the successful early stages of Orlynda's launch and positive market feedback, indicating potential for growth. However, financial challenges remain due to limited initial revenue, increased expenses, and the need for additional capital.View all ITRM earnings summaries

ITRM Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Nov<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.282,0.2603076923076923,0.2386153846153846,0.21692307692307689,0.1952307692307692,0.17353846153846153,0.15184615384615383,0.13015384615384612,0.10846153846153844,0.08676923076923077,0.06507692307692306,0.043384615384615355,0.021692307692307677,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.282,0.2603076923076923,0.2386153846153846,0.21692307692307689,0.1952307692307692,0.17353846153846153,0.15184615384615383,0.13015384615384612,0.10846153846153844,0.08676923076923077,0.06507692307692306,0.043384615384615355,0.021692307692307677,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.282,0.2603076923076923,0.2386153846153846,0.21692307692307689,0.1952307692307692,0.17353846153846153,0.15184615384615383,0.13015384615384612,0.10846153846153844,0.08676923076923077,0.06507692307692306,0.043384615384615355,0.021692307692307677,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.969,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.732,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.669,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.451,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.335,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.282,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >